LONDON, April 1, 2016 /PRNewswire/ --
BTG plc (LSE: BTG), a global specialist healthcare company,
today announced the launch of LC Bead LUMI™ in the US, the first
commercially available radiopaque embolic bead for the embolization
of hypervascular tumors and arteriovenous malformations (AVMs). LC
Bead LUMI™ is a next generation development of LC Bead®,
the market leading embolic bead.
(Logo:
http://photos.prnewswire.com/prnh/20160203/329110LOGO )
The unique visibility of LC Bead LUMI™ during and after
embolization supports the optimization of patient treatment by
enabling real-time visible confirmation of bead location during the
procedure. This provides interventional radiologists more control,
while at the same time facilitating discovery of regions of
under-treatment, allowing precise evaluation of the completeness of
tumor treatment and enhanced end-point determination, with
long-lasting radiopacity to support follow-up management.
"The launch of LC Bead LUMI™ has the potential to be a real
game-changer in the field of embolization," commented Raj
Narayanan, Associate Professor of Clinical Radiology at the
University of Miami. "Not only does it
provide doctors and patients with reassurance that the tumor has
been treated in its entirety, but it allows interventional
radiologists like me to refine treatment as we go, with the
subsequent prospect of improved outcomes for patients."
LC Bead LUMI™ has been developed on the same technology platform
and to the same high standard as LC Bead®, building upon
its market leading clinical performance.
"With the launch of LC Bead LUMI™, BTG is helping to ensure
embolization technology achieves its full potential," commented
Ken Pugh, BTG Vice President,
Commercial Development and Interventional Oncology Marketing, the
Americas. "The potential benefits of LC Bead LUMI™ are significant
- it represents a new level of control and offers the unique
opportunity to individualize patient treatment in order to help
doctors see more and treat smarter, while at the same time
providing reassurance to patients that the treatment is getting to
where it needs to be. At BTG, we're passionate about the potential
of LC Bead LUMI™ and the power of interventional oncology to
improve human health."
Today's launch represents the first market commercialization for
LC Bead LUMI™, with regulatory clearances and launches planned for
additional radiopaque bead products worldwide.
Visit us at SIR 2016 in Vancouver, and learn more about LC Bead LUMI™
during our Symposium - AS WE
"SEE" IT: LC BEAD LUMI™
CLINICAL EXPERIENCE FROM EARLY USERS (Tuesday
5th April, 12pm, Room 121/122).
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing
international specialist healthcare company. As medicine moves from
major surgery to minor procedure, from the systemic to the local,
no company endeavors to do more than BTG Interventional Medicine to
help doctors in their quest to see more, reach further and treat
smarter. Our growing portfolio of Interventional Medicine products
is designed to advance the treatment of liver tumors, advanced
emphysema, severe blood clots, and varicose veins. To learn more
about BTG Interventional Medicine, please visit: btg-im.com.
About LC Bead
LUMI™
LC Bead LUMI™ is the first commercially
available radiopaque embolic bead cleared by the US Food & Drug
Administration (FDA) for the embolization of hypervascular tumors
and arteriovenous malformations (AVMs). LC Bead LUMI™ provides
visible confirmation of bead location during the procedure. The
lasting radiopacity of LC Bead LUMI™ means they will also be
visible in follow-up scans. For instructions for use and important
safety information, please visit: LCBeadLUMI.com
SOURCE BTG plc